



09 January 2025

ImmuPharma PLC
("ImmuPharma" or the "Company")

Immupharma Announces Breakthrough Findings into Autoimmune Diseases

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company's R&D subsidiary ImmuPharma Biotech, has yielded data that provides novel insights into autoimmune disease mechanisms.

Importantly for our autoimmune therapy P140, especially for our lead indication in SLE, these findings pave the way for:

- **Earlier and more accurate diagnostics**
- **Identifying patients most likely to respond to P140 therapy**
- **Improved monitoring of the patient's response to treatment with P140**

Through this research, the company is making a significant step towards personalised medicine in SLE and other autoimmune diseases.

The Company is not at this time releasing detailed data as these findings form part of the ongoing expansion of our intellectual property portfolio including additional patents for P140.

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma said:*"We are delighted to share these significant findings from ImmuPharma Biotech. This breakthrough research confirms our confidence in P140, its future therapeutic success and also creates potential new opportunities to strengthen our intellectual property portfolio, positioning us at the forefront of innovation in autoimmune disease therapies."*

Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma Biotech said:*"The findings we have announced today highlight the extremely diligent and focused research we have been conducting behind the scenes at Immupharma Biotech in order to better characterise and explain our lead asset P140 and its application in autoimmune diseases, which is now gaining significant attention within the biopharmaceutical industry."*

Ends

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650
+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin

+44 (0) 203 368 3550

Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob Pountney

+44 (0) 20 3650 3650

SI Capital (Joint Broker)
Nick Emerson

+44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.

About Lupus (Systemic Lupus Erythematosus / SLE)

Lupus is a chronic inflammatory disease which is thought to affect some 16 million individuals worldwide. The current standard of care still consists of steroid and anti-malarial therapies which have side-effects and poor response in many patients. Recently more targeted monoclonal therapies are GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There still exists a high unmet medical need for a drug that has a strong efficacy and safety profile.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUKONRVSUARRR